Kratzke R A, Otterson G A, Lincoln C E, Ewing S, Oie H, Geradts J, Kaye F J
Division of Hematology/Oncology, Minneapolis Department of Veterans Affairs (VA) Medical Center, MN, USA.
J Natl Cancer Inst. 1995 Dec 20;87(24):1870-5. doi: 10.1093/jnci/87.24.1870.
The identification in 1994 of the CDKN2 gene as a target for mutations in a wide range of human cancers, including malignant mesothelioma, has been controversial because subsequent studies have detected a lower frequency of CDKN2 gene mutations in primary tumors than in cultured cell lines. These reports raised the hypothesis that another gene, distinct from CDKN2, might be the target of the chromosome 9p21 deletions frequently observed in these tumors.
To address whether inactivation of CDKN2 function is an essential event in the etiology of malignant mesothelioma, we examined p16INK4 protein expression in primary thoracic mesotheliomas, in nonmalignant pleural tissues, and in independent mesothelioma cell lines. We also studied the growth rate of tumor cell lines following stable transfection of CDKN2 gene.
Retinoblastoma (Rb) and p16INK4 protein expression was determined by immunohistochemical analysis from archival paraffin specimens of 12 primary thoracic mesotheliomas and a nonmalignant pleural biopsy specimen. In addition, protein immunoblot analysis for Rb and p16INK4 expression was conducted on 15 independent mesothelioma cell lines, and the ability of a transfected CDKN2 gene to suppress the growth of the mesothelioma cell lines H2373 and H2461 in vitro was examined.
We demonstrated abnormal p16INK4 expression in 12 of 12 primary mesothelioma specimens and in 15 of 15 mesothelioma cell lines. All tumor specimens and the tumor cell lines showed expression of wild-type Rb protein. In addition, we have confirmed the ability of a transfected CDKN2 gene to suppress growth of two independent mesothelioma cell lines.
Immunohistochemical analysis of the p16INK4 gene product is feasible in archival biopsy samples. With this analysis, CDKN2 gene inactivation can be determined in tumors that are contaminated with nonmalignant cells. Furthermore, since loss of p16INK4 protein expression can result from both genetic (gene mutations) and epigenetic (abnormal DNA hypermethylation) mechanisms, as we and others have shown recently, examination of protein expression is a highly sensitive method for analyzing the CDKN2 status in large numbers of tumor samples.
This study suggests that inactivation of the CDKN2 gene is an essential step in the etiology of malignant mesotheliomas. Defining the role of the p16INK4:Rb tumor suppressor pathway and its immediate downstream substrates will be an important goal in designing future therapeutic strategies.
1994年,CDKN2基因被鉴定为包括恶性间皮瘤在内的多种人类癌症的突变靶点,但这一结论存在争议,因为后续研究发现原发性肿瘤中CDKN2基因突变的频率低于培养的细胞系。这些报告提出了一个假设,即除CDKN2基因外,另一个基因可能是这些肿瘤中经常观察到的9号染色体p21缺失的靶点。
为了探讨CDKN2功能失活是否是恶性间皮瘤病因中的一个关键事件,我们检测了原发性胸段间皮瘤、非恶性胸膜组织及独立的间皮瘤细胞系中p16INK4蛋白的表达。我们还研究了稳定转染CDKN2基因后肿瘤细胞系的生长速率。
通过免疫组化分析12例原发性胸段间皮瘤存档石蜡标本及1例非恶性胸膜活检标本中的视网膜母细胞瘤(Rb)和p16INK4蛋白表达。此外,对15个独立的间皮瘤细胞系进行Rb和p16INK4表达的蛋白免疫印迹分析,并检测转染的CDKN2基因体外抑制间皮瘤细胞系H2373和H2461生长的能力。
我们发现12例原发性间皮瘤标本中的12例以及15个间皮瘤细胞系中的15个均存在p16INK4表达异常。所有肿瘤标本和肿瘤细胞系均表达野生型Rb蛋白。此外,我们证实了转染的CDKN2基因能够抑制两个独立的间皮瘤细胞系的生长。
对存档活检样本进行p16INK4基因产物的免疫组化分析是可行的。通过这种分析,可以在被非恶性细胞污染的肿瘤中确定CDKN2基因失活情况。此外,正如我们和其他人最近所表明的,由于p16INK4蛋白表达缺失可能由遗传(基因突变)和表观遗传(异常DNA高甲基化)机制导致,因此检测蛋白表达是分析大量肿瘤样本中CDKN2状态的一种高度灵敏的方法。
本研究提示CDKN2基因失活是恶性间皮瘤病因中的一个关键步骤。明确p16INK4:Rb肿瘤抑制通路及其直接下游底物的作用将是设计未来治疗策略的一个重要目标。